Ginkgo Bioworks Hldgs Inc (DNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -547,029 | -892,869 | -2,106,372 | -1,836,642 | -126,723 |
| Depreciation Amortization | 110,878 | 70,507 | 42,552 | 29,076 | 13,864 |
| Income taxes - deferred | -936 | -801 | -14,609 | N/A | N/A |
| Accounts receivable | -4,725 | 50,068 | 55,024 | -114,094 | -14,228 |
| Accounts payable and accrued liabilities | 4,771 | -1,183 | -10,844 | -2,247 | 7,019 |
| Other Working Capital | -89,670 | 29,837 | -37,006 | -61,537 | -26,515 |
| Other Operating Activity | 207,126 | 448,941 | 1,819,057 | 1,731,626 | 10,753 |
| Operating Cash Flow | $-319,585 | $-295,500 | $-252,198 | $-253,818 | $-135,830 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -61,893 | -36,373 | -52,271 | -56,521 | -57,821 |
| Net Acquisitions | -5,400 | N/A | 74,728 | -12,040 | N/A |
| Purchase Of Investment | 4,519 | N/A | -3,691 | -5,000 | N/A |
| Other Investing Activity | 538 | -44,320 | -86,160 | 304 | -9,300 |
| Investing Cash Flow | $-62,236 | $-80,693 | $-67,394 | $-73,257 | $-67,121 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -897 | -1,295 | -1,237 | -1,123 | -748 |
| Common Stock Issued | 84 | 93 | 99,543 | 167 | 26 |
| Common Stock Repurchased | N/A | N/A | N/A | -24,998 | N/A |
| Other Financing Activity | -926 | -2,014 | -2,969 | 1,560,099 | 91,040 |
| Financing Cash Flow | $-1,739 | $-3,216 | $95,337 | $1,534,145 | $90,318 |
| Exchange Rate Effect | -281 | -588 | 908 | -19 | N/A |
| Beginning Cash Position | 989,584 | 1,369,581 | 1,592,928 | 385,877 | 498,510 |
| End Cash Position | 605,743 | 989,584 | 1,369,581 | 1,592,928 | 385,877 |
| Net Cash Flow | $-383,841 | $-379,997 | $-223,347 | $1,207,051 | $-112,633 |
| Free Cash Flow | |||||
| Operating Cash Flow | -319,585 | -295,500 | -252,198 | -253,818 | -135,830 |
| Capital Expenditure | -62,541 | -40,801 | -52,271 | -56,521 | -57,821 |
| Free Cash Flow | -382,126 | -336,301 | -304,469 | -310,339 | -193,651 |